Maxion Therapeutics
maxiontherapeutics.comLocations
Streetly End, Cambridge CB21 4RP, UK
industry
Biotechnology
Size
11-50 employees
Stage
Series A
founded in
2020
Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.
Something looks off?Open jobs at Maxion Therapeutics
On-site & Remote
Job function
Seniority
Salary